Glükóz Pharmaregist (Glucose Monohydrate)

Glükóz Pharmaregist is used primarily to restore or maintain blood glucose levels in patients who cannot obtain adequate glucose orally or enterally.

• Treatment of hypoglycemia in emergency or perioperative settings.
• Provision of caloric support during prolonged fasting or before surgery.
• Dilution and carrier for compatible intravenous medications requiring a glucose base.
• Support of metabolic needs in patients receiving parenteral nutrition.
• Management of glucose deficits in critically ill or trauma patients.
• Stabilization of blood glucose during diagnostic procedures that require sedation.

The safety profile of Glükóz Pharmaregist reflects the typical reactions associated with intravenous glucose administration.

Common

• Transient hyperglycemia that resolves with monitoring.
• Mild irritation at the injection site.
• Nausea or vomiting if administered rapidly.
• Temporary electrolyte shifts, such as low potassium.
• Mild headache during infusion.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Hypersensitivity reactions, including rash or anaphylaxis.
• Fluid overload causing pulmonary edema.
• Severe metabolic acidosis in patients with impaired glucose utilization.

When using Glükóz Pharmaregist, healthcare professionals should assess patient-specific factors and monitor relevant parameters to minimize risks.

• Verify blood glucose levels before and during infusion to avoid excessive hyperglycemia.
• Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload.
• Use caution in individuals with known hypersensitivity to glucose solutions.
• Monitor electrolytes, especially potassium, as rapid glucose infusion can shift serum levels.
• Avoid concurrent administration with high‑dose insulin without appropriate glucose monitoring.
• Consider alternative carbohydrate sources for patients with hereditary fructose intolerance.

Glükóz Pharmaregist may interact with other intravenous agents, requiring attention to compatibility and metabolic effects.

Avoid

• Co‑administration with hypertonic dextrose solutions that could cause severe hyperglycemia.
• Mixing with calcium‑containing solutions that may precipitate calcium phosphate.

Use with caution

• Concurrent insulin therapy, which may increase the risk of rapid glucose fluctuations.
• Electrolyte‑balancing agents such as potassium chloride, due to potential shifts in serum potassium.
• Diuretics that affect fluid balance, as excess glucose can exacerbate dehydration.